RESX News Alert Restorgenex Corporation (RESX) 3.0000 02/15/2015
Post# of 64074
Posted On: 02/15/2015 11:31:25 AM
Restorgenex Corporation (RESX) 3.0000 $RESX
RestorGenex to Present at BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 04, 5:30AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that Stephen Simes, chief executive officer of RestorGenex, is scheduled to present at the 17 Annual BIO CEO & Investor Conference in New York City. Mr. Simes will provide a corporate overview on Tuesday, February 10, at 2:30pm ET. The presentation will be webcast and available at http://www.veracast.com/webcasts/bio/ceoinves...285519.cfm.
RestorGenex Granted Orphan Drug Designation for RES-529 for Treatment of Glioblastoma Multiforme
GlobeNewswire - Wed Jan 28, 6:00AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RES-529 for the treatment of glioblastoma multiforme. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the United States. Orphan drug designation qualifies the sponsor of the product for a tax credit and seven years of marketing exclusivity.
RestorGenex Announces Presentation of Scientific Data on RES-529 for the Treatment of Glioblastoma at Keystone Symposia on PI 3-Kinase Signaling Pathways
GlobeNewswire - Fri Jan 23, 7:32AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that it presented scientific data on RES-529 for the treatment of glioblastoma multiforme (GBM) at the Keystone Symposia Series on PI 3-Kinase (PI3K) Signaling Pathways. The presentation titled "Validation of RES-529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme" was presented on January 16, 2015. RES-529 is a proprietary first-in-class PI3K/Akt/mTOR pathway inhibitor that is capable of dissociating both TORC1 and TORC2.
RestorGenex to Present at Noble Financial Capital Markets' Eleventh Annual Equity Conference
Business Wire - Fri Jan 16, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology, and dermatology, today announced that Stephen Simes, chief executive officer of RestorGenex, will present a corporate update at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 20, 2014 at 10:00 am Eastern Standard Time.
RestorGenex to Present Glioblastoma Data at Keystone Conference on PI 3-Kinase Signaling Pathways in Disease Conference
Business Wire - Tue Jan 13, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that David Sherris, Ph.D., chief scientific officer of RestorGenex, will present scientific data on the Company's proprietary RES-529 program in oncology, focusing on glioblastoma multiforme entitled, "Validation of RES-529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme." Dr. Sherris's poster presentation at the Keystone Conference on PI 3-Kinase Signaling Pathways in Disease is scheduled for Friday, January 16, 2015 from 12:00 PM - 2:30 PM (PST) at the Fairmont Hotel Vancouver, Vancouver, British Columbia.
RestorGenex to Present at Biotech Showcase 2015
Business Wire - Wed Jan 07, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the Biotech Showcase 2015 in San Francisco, CA. Mr. Simes will provide a corporate overview on Tuesday, January 13, at 3:00 pm PST. The presentation will be webcast and available at http://edge.media-server.com/m/p/3bskmh3j and will be archived at www.restorgenex.com.
RestorGenex Announces Issuance of European Patent for its Dermatology Program
Business Wire - Mon Jan 05, 6:01AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that the European Patent Office has issued to RestorGenex European Patent No. 2364700 entitled "Compositions and Methods to Treat Skin Diseases Characterized by Cellular Proliferation and Angiogenesis." The patent is directed to use of RES-529, as well as other small molecules, for preventing or treating skin diseases, as well as on the composition of matter of RES-529. RES-529 is a first-in-class allosteric dissociative TORC1/TORC2 inhibitor of the PI3K pathway, and is RestorGenex's lead candidate in development for the treatment of diseases involving cell proliferation and angiogenesis.
RestorGenex EPS of -$0.18
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:17PM CST
RestorGenex Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 3:00PM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today reported on its cash balance as of September 30, 2014 and its financial results for the third quarter of 2014.
RestorGenex to Present at Conference on Targeting Ocular Disorders
Business Wire - Mon Oct 06, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today announced that Chief Scientific Officer David Sherris, Ph.D., will present scientific data on the Company's proprietary RES-529 program in ophthalmology. Dr. Sherris's presentation at the Cambridge Healthtech Institute conference is scheduled for Monday, October 6, 2014 at 4:55 pm (EDT) at the Westin Boston Waterfront Hotel.
RestorGenex to Present at the AACR Conference on Targeting the PI3K-mTOR Network in Cancer
Business Wire - Mon Sep 15, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company initially focused on developing products for oncology, dermatology, ophthalmology and women's health, today announced that David Sherris, Ph.D., RestorGenex's chief scientific officer, will present scientific data on the Company's proprietary RES-529 program in oncology. Dr. Sherris' presentation at the American Association for Cancer Research Conference on Targeting the PI3K-mTOR Network in Cancer is scheduled for Monday, September 15, 2014 at 4:30 pm (EST) at the Sheraton Philadelphia Downtown Hotel, Philadelphia, Pennsylvania.
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
Business Wire - Thu Sep 04, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co.
RestorGenex Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 14, 3:05PM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today reported on its cash balance as of June 30, 2014 and its financial results for the second quarter of 2014.
RestorGenex Appoints Mark Weinberg, MD, MBA Senior Vice President of Clinical Development
Business Wire - Mon Aug 04, 5:30AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, announced today the appointment of Mark Weinberg MD, MBA as Senior Vice President of Clinical Development.
ABT: 46.09 (+0.87)
RestorGenex Announces Closing of its Private Placement of Common Stock
Business Wire - Tue Jul 15, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company, announced today that it closed its private placement, which raised approximately $35.6 million in gross proceeds. RestorGenex received net proceeds of approximately $31.3 million, after deducting placement agent fees and other offering expenses. RestorGenex sold 8,895,685 shares of its common stock and warrants to purchase up to 2,668,706 additional shares of its common stock in a private placement to institutional and accredited investors. Each unit, consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock, was sold for a purchase price of $4.00. Each full warrant is exercisable immediately into one common share of common stock at an exercise price of $4.80 per share and will expire four years from its date of issuance. As a result of closing this financing, RestorGenex currently has outstanding approximately 18.4 million shares of common stock and 24.5 million fully diluted shares.
RestorGenex Announces Management Changes
Business Wire - Wed Jul 09, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, announced today several management changes.
ANIP: 62.69 (-0.43)
RestorGenex to Present at BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 04, 5:30AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that Stephen Simes, chief executive officer of RestorGenex, is scheduled to present at the 17 Annual BIO CEO & Investor Conference in New York City. Mr. Simes will provide a corporate overview on Tuesday, February 10, at 2:30pm ET. The presentation will be webcast and available at http://www.veracast.com/webcasts/bio/ceoinves...285519.cfm.
RestorGenex Granted Orphan Drug Designation for RES-529 for Treatment of Glioblastoma Multiforme
GlobeNewswire - Wed Jan 28, 6:00AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RES-529 for the treatment of glioblastoma multiforme. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the United States. Orphan drug designation qualifies the sponsor of the product for a tax credit and seven years of marketing exclusivity.
RestorGenex Announces Presentation of Scientific Data on RES-529 for the Treatment of Glioblastoma at Keystone Symposia on PI 3-Kinase Signaling Pathways
GlobeNewswire - Fri Jan 23, 7:32AM CST
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that it presented scientific data on RES-529 for the treatment of glioblastoma multiforme (GBM) at the Keystone Symposia Series on PI 3-Kinase (PI3K) Signaling Pathways. The presentation titled "Validation of RES-529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme" was presented on January 16, 2015. RES-529 is a proprietary first-in-class PI3K/Akt/mTOR pathway inhibitor that is capable of dissociating both TORC1 and TORC2.
RestorGenex to Present at Noble Financial Capital Markets' Eleventh Annual Equity Conference
Business Wire - Fri Jan 16, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology, and dermatology, today announced that Stephen Simes, chief executive officer of RestorGenex, will present a corporate update at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 20, 2014 at 10:00 am Eastern Standard Time.
RestorGenex to Present Glioblastoma Data at Keystone Conference on PI 3-Kinase Signaling Pathways in Disease Conference
Business Wire - Tue Jan 13, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that David Sherris, Ph.D., chief scientific officer of RestorGenex, will present scientific data on the Company's proprietary RES-529 program in oncology, focusing on glioblastoma multiforme entitled, "Validation of RES-529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme." Dr. Sherris's poster presentation at the Keystone Conference on PI 3-Kinase Signaling Pathways in Disease is scheduled for Friday, January 16, 2015 from 12:00 PM - 2:30 PM (PST) at the Fairmont Hotel Vancouver, Vancouver, British Columbia.
RestorGenex to Present at Biotech Showcase 2015
Business Wire - Wed Jan 07, 6:00AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the Biotech Showcase 2015 in San Francisco, CA. Mr. Simes will provide a corporate overview on Tuesday, January 13, at 3:00 pm PST. The presentation will be webcast and available at http://edge.media-server.com/m/p/3bskmh3j and will be archived at www.restorgenex.com.
RestorGenex Announces Issuance of European Patent for its Dermatology Program
Business Wire - Mon Jan 05, 6:01AM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that the European Patent Office has issued to RestorGenex European Patent No. 2364700 entitled "Compositions and Methods to Treat Skin Diseases Characterized by Cellular Proliferation and Angiogenesis." The patent is directed to use of RES-529, as well as other small molecules, for preventing or treating skin diseases, as well as on the composition of matter of RES-529. RES-529 is a first-in-class allosteric dissociative TORC1/TORC2 inhibitor of the PI3K pathway, and is RestorGenex's lead candidate in development for the treatment of diseases involving cell proliferation and angiogenesis.
RestorGenex EPS of -$0.18
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:17PM CST
RestorGenex Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 3:00PM CST
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today reported on its cash balance as of September 30, 2014 and its financial results for the third quarter of 2014.
RestorGenex to Present at Conference on Targeting Ocular Disorders
Business Wire - Mon Oct 06, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today announced that Chief Scientific Officer David Sherris, Ph.D., will present scientific data on the Company's proprietary RES-529 program in ophthalmology. Dr. Sherris's presentation at the Cambridge Healthtech Institute conference is scheduled for Monday, October 6, 2014 at 4:55 pm (EDT) at the Westin Boston Waterfront Hotel.
RestorGenex to Present at the AACR Conference on Targeting the PI3K-mTOR Network in Cancer
Business Wire - Mon Sep 15, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company initially focused on developing products for oncology, dermatology, ophthalmology and women's health, today announced that David Sherris, Ph.D., RestorGenex's chief scientific officer, will present scientific data on the Company's proprietary RES-529 program in oncology. Dr. Sherris' presentation at the American Association for Cancer Research Conference on Targeting the PI3K-mTOR Network in Cancer is scheduled for Monday, September 15, 2014 at 4:30 pm (EST) at the Sheraton Philadelphia Downtown Hotel, Philadelphia, Pennsylvania.
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
Business Wire - Thu Sep 04, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co.
RestorGenex Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 14, 3:05PM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today reported on its cash balance as of June 30, 2014 and its financial results for the second quarter of 2014.
RestorGenex Appoints Mark Weinberg, MD, MBA Senior Vice President of Clinical Development
Business Wire - Mon Aug 04, 5:30AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, announced today the appointment of Mark Weinberg MD, MBA as Senior Vice President of Clinical Development.
ABT: 46.09 (+0.87)
RestorGenex Announces Closing of its Private Placement of Common Stock
Business Wire - Tue Jul 15, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company, announced today that it closed its private placement, which raised approximately $35.6 million in gross proceeds. RestorGenex received net proceeds of approximately $31.3 million, after deducting placement agent fees and other offering expenses. RestorGenex sold 8,895,685 shares of its common stock and warrants to purchase up to 2,668,706 additional shares of its common stock in a private placement to institutional and accredited investors. Each unit, consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock, was sold for a purchase price of $4.00. Each full warrant is exercisable immediately into one common share of common stock at an exercise price of $4.80 per share and will expire four years from its date of issuance. As a result of closing this financing, RestorGenex currently has outstanding approximately 18.4 million shares of common stock and 24.5 million fully diluted shares.
RestorGenex Announces Management Changes
Business Wire - Wed Jul 09, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, announced today several management changes.
ANIP: 62.69 (-0.43)
(0)
(0)Scroll down for more posts ▼